Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

Core Insights - Alkermes plc is set to present three posters related to ALKS 2680 at the SLEEP 2024 conference, highlighting its investigational oral orexin 2 receptor agonist for narcolepsy treatment [1][3] Group 1: ALKS 2680 Development - ALKS 2680 is being developed as a once-daily treatment for narcolepsy, targeting the orexin 2 receptor to improve wakefulness and control cataplexy [6][8] - The company will present data from a phase 1b study involving 10 patients with narcolepsy type 1, focusing on safety and pharmacodynamic efficacy [1][3] - The Vibrance-1 study is a phase 2 clinical trial comparing ALKS 2680 to placebo in patients with narcolepsy type 1, recently initiated following proof-of-concept data [3][7] Group 2: Patient Insights - Findings from qualitative interviews with 22 patients (12 with narcolepsy type 1 and 10 with type 2) will be presented, detailing the disease's impact on various life aspects [2][3] - The interviews aimed to uncover the burden of narcolepsy on work, mental health, daily activities, and relationships [2][3] Group 3: Presentation Details - The presentations at SLEEP 2024 include specific poster sessions on the safety and pharmacodynamic effects of ALKS 2680, study design for Vibrance-1, and patient perspectives on living with narcolepsy [4][5]